Blue Trust Inc. Sells 874 Shares of HUTCHMED (China) Limited Sponsored ADR $HCM

Blue Trust Inc. lowered its stake in HUTCHMED (China) Limited Sponsored ADR (NASDAQ:HCM) by 20.8% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 3,330 shares of the company’s stock after selling 874 shares during the quarter. Blue Trust Inc.’s holdings in HUTCHMED were worth $50,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently made changes to their positions in HCM. Summit Trail Advisors LLC lifted its holdings in shares of HUTCHMED by 7.7% in the first quarter. Summit Trail Advisors LLC now owns 14,094 shares of the company’s stock worth $212,000 after acquiring an additional 1,004 shares during the last quarter. Crossmark Global Holdings Inc. increased its stake in shares of HUTCHMED by 31.4% in the first quarter. Crossmark Global Holdings Inc. now owns 24,420 shares of the company’s stock valued at $367,000 after buying an additional 5,829 shares during the period. XY Capital Ltd increased its stake in shares of HUTCHMED by 142.4% in the first quarter. XY Capital Ltd now owns 113,136 shares of the company’s stock valued at $1,702,000 after buying an additional 66,460 shares during the period. Vident Advisory LLC increased its stake in shares of HUTCHMED by 78.3% in the first quarter. Vident Advisory LLC now owns 19,728 shares of the company’s stock valued at $297,000 after buying an additional 8,664 shares during the period. Finally, Goldman Sachs Group Inc. increased its stake in shares of HUTCHMED by 8.5% in the first quarter. Goldman Sachs Group Inc. now owns 93,919 shares of the company’s stock valued at $1,413,000 after buying an additional 7,342 shares during the period. Institutional investors own 8.82% of the company’s stock.

Analysts Set New Price Targets

Several research analysts have recently issued reports on HCM shares. Bank of America upped their price objective on HUTCHMED from $27.00 to $28.00 and gave the company a “buy” rating in a research note on Tuesday, July 22nd. Zacks Research downgraded HUTCHMED from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, September 9th. Wall Street Zen raised HUTCHMED from a “hold” rating to a “buy” rating in a research note on Saturday, October 11th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of HUTCHMED in a research note on Wednesday, October 8th. Finally, Morgan Stanley downgraded HUTCHMED from an “equal weight” rating to an “underweight” rating and lowered their price objective for the company from $18.00 to $13.75 in a research note on Monday, September 22nd. One equities research analyst has rated the stock with a Buy rating, three have given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Hold” and an average target price of $20.88.

HUTCHMED Trading Down 1.7%

Shares of HCM stock opened at $15.14 on Friday. HUTCHMED has a 52 week low of $11.51 and a 52 week high of $21.50. The company has a quick ratio of 4.51, a current ratio of 4.65 and a debt-to-equity ratio of 0.05. The firm has a 50 day moving average of $15.95 and a 200-day moving average of $15.48.

HUTCHMED Company Profile

HUTCHMED (China) Ltd. is a holding company, which engages in the research and development, manufacture, and sale of pharmaceuticals and health-oriented consumer products. It operates through the Oncology/Immunology and Other Ventures segments. The Oncology/Immunology segment includes the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases.